A detailed history of Amalgamated Bank transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Amalgamated Bank holds 943 shares of URGN stock, worth $11,768. This represents 0.0% of its overall portfolio holdings.

Number of Shares
943
Previous 943 -0.0%
Holding current value
$11,768
Previous $14,000 14.29%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$13.81 - $19.33 $31,693 - $44,362
-2,295 Reduced 70.88%
943 $14,000
Q4 2023

Feb 06, 2024

BUY
$10.87 - $15.93 $5,065 - $7,423
466 Added 16.81%
3,238 $49,000
Q2 2023

Aug 11, 2023

BUY
$8.75 - $14.29 $24,255 - $39,611
2,772 New
2,772 $28,000
Q2 2022

Aug 15, 2022

SELL
$5.12 - $8.74 $15,155 - $25,870
-2,960 Closed
0 $0
Q1 2022

Jun 30, 2022

BUY
$5.92 - $9.73 $17,523 - $28,800
2,960 New
2,960 $26,000

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $284M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.